PCRI Insights February 2005 vol. 8, no. 1
By Douglas O. Chinn, MD,
Chinn & Chinn Urology Medical Associates
See end of article for June 2006 and August 2008 updates.
What is HIFU?
HIFU, which stands for High Intensity Focused Ultrasound, was first developed as a treatment of benign prostatic hyperplasia (BPH) and now is also being used as a procedure for the killing of prostate cancer cells. As shown in Figure 1, this procedure utilizes transrectal ultrasound that is highly focused into a small area, creating intense heat of 80-100° C, which is lethal to prostate cancer tissue. Since ultrasound is non-ionizing (as opposed to ionizing in radiation), tissue in the entry and exit path of the HIFU beam is not injured.
|Figure 1 Focusing of Transrectal Ultrasound to Create Lethal Heat to Malignant Tissue. Image above: courtesy of Focus Surgery® Image below: courtesy of Sanghvi et al 6|
The published clinical experience with HIFU for this application is limited and only extends out to 5 years, and the procedure is not yet approved by the FDA for use in the United States, (HIFU is approved in Europe, China, Japan, Caribbean, Mexico, and Latin America). However, HIFU offers a powerful advantage over radiation treatment: The control and precision of HIFU allow the accomplished surgeon to accurately target the tissue to be destroyed without injuring adjacent tissue. HIFU destroys tissue by heat, rather than by cavitation or mechanical shearing forces.
Energy pulses over 100 watts/pulse are usually required to thermally ablate tissue.1 The predominant desired effect is thermal, as contrasted to cavitation or mechanical forces. The energy or thermal delivery dose occurs in less than 1 second, and is very controlled and well defined. The temperature immediately rises up to 70-80° C,and proceeds to thermally ablate the tissue. The surrounding tissue, which is 2 mm away from the focused lesion, is not injured. Although each lesion is small, (2 mm x 3 mm x 30 mm) sequential dosing results in a larger volume of ablated tissue.2
Attenuation or weakening of the HIFU by the intervening tissue can occur. The density and content of the intervening tissue can affect the HIFU power. Bone or calcification can severely attenuate and even reflect HIFU output. Air not only attenuates HIFU, but interferes with imaging as well.
Background and History
Since the 1940s, HIFU has been viewed as a potential therapeutic tool, and the initial work on its role in the treatment of the benign prostatic hypertrophy (BPH) began in the early 1990s. In what I consider a landmark study, Sanghvi et al did several safety and feasibility studies on canine prostates, utilizing HIFU and thermal mapping.3 From 1992-93, the first group of patients was treated at Indiana University, School ofMedicine, by Bihrle et al.4
The role of HIFU for treating prostate cancer also picked up momentum after that. Since then, several clinical outcome studies have recently been published, including a 5-year outcome study by Blana et al,5 and a multi-center European study by Thuroff et al.6
Currently, there are two companies that make HIFU units for patient use: Focus Surgery® and EDAP Technomed®. Focus Surgery® is based in the United States, and EDAP Technomed® is based in France. For both companies, the HIFU unit consists of a control console, a power generator, a cooling system, and a probe that contains a standard imaging and a high-intensity treatment ultrasound head.
|Figure 2 Elements of the two HIFU Units.|
HIFU is performed as an outpatient procedure, usually under epidural anesthesia. As shown in Figure 3, the patient is either placed on his back with legs elevated in the dorsal lithotomy position (Sonablate 500®) or on his right side (Ablatherm®). The HIFU probe is placed into the rectum and multiple gland images are taken. Then, at the HIFU control panel, all of the images are reviewed, and the treatment zones are defined and logged into the treatment computer. The entire prostate cannot be treated all at once, so the prostate is divided into treatment zones. The entire procedure can take between 2-4 hours, depending upon the gland size.
|Figure 3 Positioning of the Sonablate 500 probe (two views). Images courtesy of Focus Surgery®|
Differences Between the Sonablate 500 and the Ablatherm Units
As shown in Figure 4, the Sonablate 500 requires three treatment zones from top to bottom, and two treatment zones from side to side. The Ablatherm unit has only one treatment zone from top to bottom, but two treatments from side to side.
|Figure 4 Treatment Zones treated with Sonablate 500. Courtesy of US HIFU.®|
The Sonablate software allows the surgeon to customize each of the six treatment zones in order to safely ablate the entire gland. As shown in Figure 5, precise HIFU lesions are overlapped side-by-side in both Sector (Transverse) and Linear (Longitudinal) planes within the prostate as defined by the doctor.
|Figure 5 The image illustrates in the Sector and Linear view,how the Sonablate® 500 HIFU beam is precisely focused and delivered into the prostate gland. Also note the multiple treatment zones required.Courtesy of Takai Hospital Supply Co.,Tokyo, Japan.|
As can be seen from the real time images in Figure 6, HIFU allows the exact placement of the treatment zones up to the edge of the gland or external sphincter. If necessary, the treatment zone can extend beyond the edge of the gland to treat early extracapsular penetration, or just up to the edge of the neurovascular bundle.
|Figure 6 Sonablate® views in the sector and linear orientation. The red box represents the planned treatment area with the vertical red lines being the exact target. The red shaded areas represent the treated areas. In the sector view, the treatment box can be accurately controlled to aim HIFU just at the lateral edge of the gland, and still avoid injuring the neurovascular bundle. In the linear view, the treatment box is controlled to end just at the apex of the prostate gland, thereby avoiding injury to the adjacent external sphincter. Photo by D. Chinn, MD.|
As shown in Figure 7, the Ablatherm device uses one large treatment zone from top to bottom. It too requires multiple treatment areas from side to side.
Figure 7 Ablatherm® sector view with treatment zones mapped out. There is only a single vertical treatment zone. In this illustration, the gland is taller than the height of the treatment zone. This image is from a BPH therapy. Courtesy of EDAP Technomed ®
With the Sonablate® unit, the patient is placed in the dorsal lithotomy position. (See Figure 8.) The patient is lying flat on his back, and his legs are elevated by behind-the-knee stirrups. The treatment console and cooling unit are separate. The Sonablate® unit uses a standard operating room table.
Figure 8 Procedure Setup with Sonablate 500. Photos by D. Chinn, MD.
With the Ablatherm® unit, the patient must lie on his right side, on a special table. (See Figure 9) The cooling unit and probe are integrated into the table. The treatment console is separate.
Figure 9 Procedure Setup – Courtesy of EDAP Technomed®
As shown in Figure 10, the Ablatherm® unit uses two ultrasound probes built into a single unit. The imaging probe (white) is used to record multiple images of the prostate in the transverse (end on view) and longitudinal (side view) planes. Once all of these images are recorded, they are used to plan out the treatment. Then in therapy mode, the imaging probe is retracted, and the treatment probe is moved into position in order to treat the planned zones.
Figure 10 Ablatherm Imaging and Treatment
Probes. Courtesy of EDAP Technomed ®
The images seen during therapy with the Ablatherm are static ultrasound images, with treatment zones superimposed. There is no live ultrasound imaging during therapy. The red lines in Figure 11 represent treated tissue, the green lines tissue to be treated. The orange-filled area represents current therapy. In order to update ultrasound images, the Treatment Probe must be retracted and the Imaging Probe must be moved back into the field.
Figure 11 Ablatherm® sector view. The treatment zone covers the gland height completely, and requires two zones to cover from side to side.Again, the HIFU beam can be precisely aimed to the lateral and posterior edges of the gland. Courtesy of EDAP Technomed ®
The Sonablate® 500 probe combines the Imaging and Treatment probes into the single unit shown in Figure 12. Therefore, during therapy, live ultrasound imaging can be utilized. This allows the physician to simultaneously image and treat, thereby ensuring that the treatment areas have not changed by any patient or probe movement. In fact, the tissue changes due to treatment can be seen during therapy.
Figure 12 Sonoblate 500 Combined Imaging and Treatment Probe. Courtesy of Focus Surgery ®
In the Figure 13 image, the treatment box is outlined in red. The area shaded red represents the areas already treated; the red vertical lines without the red shading are the planned treatment areas; and the yellow vertical line represents the next treatment area. Because of real time imaging, one can actually see the tissue changes caused by HIFU, which are the bright white spots (echoes) seen above.
|Figure 13 Sonablate linear view demonstrating real time tissue density and image changes induced by HIFU. Treated tissue turns white, while untreated tissue remains unchanged. This allows confirmation of therapy. Photo by D. Chinn, MD.|
First, the patient lies down on the operating room table and receives spinal anesthesia. The ultrasound probe is placed into the rectum and is adjusted such that all of the gland can be properly imaged. Then a series of images in the sector and linear views are captured by ultrasound, under computer control. All of the captured images are displayed on the console screen. The surgeon, using a mouse, then selects the treatment zones.
For both the Ablatherm and Sonablate units, the surgeon must make sure that the top of the gland is in the treatment zone. Depending on the extent of the cancer, the side-to-side treatment zones may extend up to the edge or beyond the prostate capsule. The surgeon must keep track of the treated zones to avoid untreated gaps occurring between the treatment zones. After one zone is treated, the probe is rotated to the untreated side of the gland. Images are recaptured, and treatment zones delineated. Treatment is then started again. Treatment ends when all of the gland has been treated.
With both units, the intensity and duration of therapy is determined by the computer, but the power can be manually adjusted by the surgeon, usually when the imaging nears the rectal wall.
There will be edema secondary to the thermal effects: therefore, at the end of the procedure, a urethral foley catheter is placed into the bladder. This catheter will remain for 2-4 weeks. There may be some bladder discomfort for several days, but full activities can be started the day following surgery.
Once the catheter is removed, the urinary stream may take several months to improve, as the urethra needs to heal, and the gland will take up to three months to start shrinking in size. During this time, some dead prostate tissue may pass in the urine. The rest of the gland forms scar tissue.
For the majority of patients, the goal of HIFU therapy is curative. Therefore, in my opinion, any patient with organ-confined prostate cancer may be a primary candidate. As with cryosurgery, HIFU can treat the entire prostate capsule and beyond, so HIFU can also be used to treat prostate cancer that has begun to spread beyond the capsule. If capsular or neurovascular bundle invasion has been detected (by DRE, Endorectal MRI, ultrasound, or biopsy) these areas can be easily and safely treated with HIFU. More importantly, if there is no capsular invasion and the neurovascular bundles are not involved, the nerves can be spared, and potency maintained (depending upon the skill of the surgeon).
Seminal vesicle invasion is a problem for all therapies because there is a higher incidence of occult metastatic disease with seminal vesicle involvement. Early seminal vesicle invasion can be treated with HIFU. As developers continue to improve and develop the HIFU equipment, I anticipate further seminal vesicle therapy.
Thus, the best candidates for curative intent are clinical/pathological stages T1c-T3, with an understanding that the higher the volume/stage, the higher the risk of occult metastatic disease. As in cryosurgery, the Gleason score does not affect the lethality of HIFU.
Due to the limited focal length of HIFU, gland volume cannot be 40cc or larger. If the gland is larger, then downsizing is required with total androgen ablation using a gonadotropin-releasing hormone (GnRH) agonist, (e.g. Zoladex®) a non-steroidal antiandrogen (e.g. Eulexin® or Casodex®), and a 5-alpha reductase inhibiter (e.g. Proscar® or Avodart®). This same protocol has been utilized for preoperative downsizing for brachytherapy and cryosurgery.
Aside from primary therapy, HIFU can be utilized as salvage therapy, primarily after radiation. With the Sonablate® unit, brachytherapy seeds do not interfere with the energy transfer. With the majority of radiation failure patients, the surrounding tissue is damaged, and the complications of incontinence, impotence, and rectal injury are increased in any form of salvage therapy (salvage radical prostatectomy or cryosurgery). Because of the excellent control and targeting of tissue afforded by HIFU, I personally feel that HIFU will emerge as the best choice for salvage therapy. To date, the reported incidence of incontinence and rectal injury is much less than for salvage radical prostatectomy or cryosurgery. If there is local recurrence after radical prostatectomy, and a lesion left behind can be visualized on ultrasound, then there is a chance that HIFU can be used to treat that lesion. HIFU can also be used for palliative therapy, debulking large symptomatic tumors that are causing pain, bleeding, and obstruction. As with cryosurgery, the effectiveness is limited by the gland size.
Also as with cryosurgery, HIFU can be repeated, without any increase in risk or complications. HIFU can also be used to treat cryosurgical failures, if there is no undue calcification present. Finally, if necessary, radical prostatectomy can be performed after HIFU.
Focal therapy is a very controversial topic among urologists with the biggest concerns being the facts that: (1) prostate cancer is multi-focal; (2) there is sampling error with biopsies; and (3) there is currently no way to find all of the cancer, even with saturation biopsies. The attraction of focal therapy is a marked decrease in side effects of the procedure because not all of the gland has to be treated. This results in decreased operating room time, less post-procedural gland swelling, and reduced urinary retention. Since only a portion of the gland is treated, all side effects are greatly reduced or absent. While the validity of focal therapy is a topic for another discussion, it can be said that, while cryosurgery is the first procedure to allow focal therapy, HIFU may offer a better form of focal therapy. HIFU can truly treat just one lobe of the gland. With cryosurgery, the surgeon must drive lethal and non-lethal ice across the midline to ensure destructive ablation of one lobe. The same methodology applies to nerve-sparing procedures. With cryosurgery, in order to preserve the neurovascular bundles, the surgeon risks preserving viable prostate tissue as well. This is less of a concern with HIFU, which can focus the ultrasound beam right up to the edge of the capsule.
As previously stated, gland size must be less than 40cc. Also, extensive or very large calcifications will interrupt, block and reflect the HIFU beam, so these glands cannot currently be treated. If there is rectal stenosis that does not allow the probe to be placed, HIFU cannot be used. A history of rectal fistula is also a current contraindiction. If a patient had a prior rectal fistula, it may not be completely healed. Also, the damaged tissue may have less vascular reserve and be more susceptible to injury than normal tissue. Moreover, if the fistula recurs after HIFU, it might be erroneously blamed upon the procedure.
Again, as in cryosurgery, bleeding problems or anticoagulation are not absolute contraindications. It is recommended that all blood thinners be stopped 10 days in advance, because there may be some rectal bleeding from the stretching caused by the rectal probe. However, the blood thinners can be restarted 24-48 hours later. If there is a bleeding diathesis (lack of clotting factors) the corrective factors can be infused just before surgery.
Risks and Complications
Immediately after surgery, there will be urinary retention, because the gland will swell. Often, there will be necrosis (slough) of some or all of the urethra. Many patients pass this tissue without any problems, and others may require the removal of the tissue through a cystoscope (TURP). (Sloughing can also occur with cryosurgery, especially in radiation failure. Radiation necrosis of the urethra has been seen with brachytherapy, but no surgery is performed due to the high risk of problems in radiated tissue and the seeds.)
Table 1 presents the treatment side effects of HIFU and compares them with three other leading treatments. As shown, incontinence is extremely rare, especially with the Sonablate 500®. This is even more important in radiation failure patients, where the accuracy and precision in which HIFU can be delivered is very important.
Potency after HIFU can be good, again for the above mentioned reasons. Moreover, the equipment manufacturers are continuing to work on methods to improve the chances of maintaining potency after HIFU. However, as with cryosurgery or radical prostatectomy, all patients undergoing HIFU will have no ejaculation with climax, and they will be infertile.
Rectal injury appears to no longer be a significant concern for HIFU. Although early papers reported rectal fistula rates as high as 5% with earlier prototype equipment, series using the newest technology have observed rates of <0.5% (for the Sonablate 500). Hence, with the current HIFU units, the incidence should be very low. Of course, due to the surrounding tissue effects of radiation, there is still a risk of rectal injury. But, just as with cryosurgery, it depends upon the skill of the surgeon to plan and control HIFU to avoid rectal injury.
When I started performing cryosurgery in 1993, there was a paucity of published data from multiple centers. Also, high-quality basic scientific studies on the technique and technology of cryosurgery, specifically for prostate, were severely lacking. It took clinicians such as myself with the support of Drs. Fred Lee Sr., Fred Lee Jr., Wilson Wong and Duke Bahn to develop the proper way to freeze the prostate gland. Until we developed the technology and technique of temperature monitoring, the excellent and consistent success of cryosurgery was unobtainable. Conversely, there have been excellent scientific and clinical publications with HIFU, notably these published journal articles by Sanghvi,3,7 Chaussey,8 Vallancien,9 Gelet,10 Blana5 and others.11,12,13,6 Finally, the equipment hardware and software are at a much more sophisticated level at this point than they were at this stage of started cryosurgery development.
Table 2, modified from Katz and Rewcastle,31 compares (1) the 5-year biochemical disease-free survival rates as published since 1992 for five prostate cancer local treatments with (2) that published by Gelet et al32 for HIFU. As can be seen, HIFU results compare well with the results of these established therapies, particularly in view of the low side-effects advantages presented in Table 1. Moreover, the results of the HIFU patient series can be considered a worst case scenario, as the series includes the first patients ever to undergo HIFU as a therapy for prostate cancer, and many of them were treated with the original prototype HIFU.
HIFU and the FDA
HIFU has not yet been approved by the FDA for use in the United States, but it is approved for use in Europe, Latin America, the Caribbean, China, and Japan. FDA clinical phase trials I and II have been done in the United States, and plans are underway to start the final Phase III FDA clinical trials. Therefore, HIFU is not available in the United States. HIFU therapy with the Sonablate 500® is available in Santiago, Dominican Republic, Puerto Vallarta, and Los Cabos San Lucas. In Cabo, the hospital is AmeriMed, which is an American-owned hospital chain in Mexico.
Although HIFU is a relatively new procedure for prostate cancer treatment, it represents what may become the next generation of minimally invasive therapy for prostate cancer. While clinical experience with HIFU is still limited, the technology has been extensively studied and developed to the point that I personally believe that it is indeed ready for prime time. The control and precision that HIFU provides truly allows the surgeon to precisely ablate the prostate gland with pinpoint accuracy and thereby preserve the adjacent structures. Furthermore, because HIFU is non-ionizing, there is no collateral tissue damage. Despite not being FDA-approved in the U.S., HIFU remains my first choice for therapy in radiation failure, focal therapy, and potency sparing surgery. For all other cases, it is my relative first choice depending on my patients’ desire.
The development of obstruction and possibly sloughing is the most common side effect of HIFU. Many European centers are performing prostate incisions or TURPs prior to HIFU in an attempt to alleviate this problem. I anticipate changes in the technique and perhaps new developments in equipment that may resolve this issue. Improvements in technology will more easily allow the surgeon to fit all of the currently rectangular treatment box into the elliptical shape of the prostate. This will undoubtedly improve our ability to totally ablate the entire prostate gland.
Of course, longer term follow-up and clinical experience is required, and as with any therapy, not everyone is going to have a local cure. However, in my opionion, HIFU should be seriously considered in the primary treatment of prostate cancer, and I feel it should be the first choice for radiation failure cases.
HIFU Update – posted June 22, 2006
Many patients have been asking about the current status of HIFU and the FDA, and therefore I am providing an update of this process. The Ablatherm FDA Phase III clinical trial for high intensity focused ultrasound therapy for primary, untreated prostate cancer is now underway and actively recruiting patients. See updated trial description below. For further details and treatment site locations, please go to http://clinicaltrials.gov/ct/show/NCT00295802?order=2, “Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer.”
For patients who have failed radiation therapy for prostate cancer, there is another FDA clinical trial that is underway. This is a single arm FDA Phase I clinical trial. This means that after successful completion of this study, another FDA study (typically a combined Phase II and III study) will be required before full FDA approval is possible. This study is also actively recruiting patients. For further details and treatment site locations, please go to http://clinicaltrials.gov/ct/show/NCT00030277?order=1, “High-Intensity Focused Ultrasound in Treating Patients With Locally Recurrent Prostate Cancer.”
HIFU Update – provided August 2008 by agent for EDAP Technomed, Inc.
Nationwide Prostate Cancer Study Being Conducted
Researchers are currently conducting a study to compare the effectiveness of two procedures in treating low-risk, localized prostate cancer. Volunteers needed to participate in this clinical research study.
One of the procedures being tested is cryotherapy (freeze therapy), a commonly used minimally invasive treatment for localized prostate cancer that already is approved for treatment by the U.S. Food and Drug Administration (FDA). In the study, cryotherapy will be compared with an investigational procedure that uses high-intensity focused ultrasound (HIFU). This procedure is not approved by the FDA. This comparison will help researchers and the FDA understand if HIFU is as safe and effective as cryotherapy.
Previous studies of this form of HIFU treatment conducted among men with low-risk prostate cancer in Europe have shown negative biopsy rates ranging from 82 to 93 percent. Approximately 13,000 men have been treated to-date with HIFU worldwide.
A number of treatment options are available to men with low-risk prostate cancer, including prostatectomy, radiotherapy, and cryotherapy. Each comes with its own side effects that must be weighed carefully by men and their spouses and families when making treatment decisions.
In the last several years, minimally invasive treatment options, of which cryotherapy is one, have been examined more closely to determine what benefits they may offer over other standard therapies. The goal of minimally invasive options is to reduce the impact of the treatment on the patient, resulting in quicker recovery and fewer side effects, while maintaining the effectiveness of standard treatments.
To be eligible to participate in the study, volunteers must meet specific criteria, including having a diagnosis of localized prostate cancer and being a male, aged 60 or older. To learn more about the study, call toll-free at 1-800-288-0031 or visit www.PCaResearch.com.
 Chaussy et al Curr Urol Rep. 2003; 4(3):248-52;
 Blana et al Urology. 2004; 63(2):297-300;
1.Watkin NA, Ter Haar GR, et al: The Urologic Applications of Focused 14.Ultrasound Surgery, Br J Urol. 1995:75 (suppl 1):1-8.
2. Chan DY, Solomon SB., Noninvasive Therapy with High-Intensity Focused Ultrasound, Surgical Rounds, 527-532,November 2002.
3. Sanghvi N, Fry F, Noninvasive Surgery of Prostate Tissue by High- Intensity Focused Ultrasound, IEEE Transactions on Ultrasound, Ferroelectrics, and Frequency Control, 43 (6) 1099-1996,November 1996.
4. Bihrle R, Foster RS, et al: High Intensity Focused ultrasound for the Treatment of BPH : Early U.S. Clinical Experience, J. Urology 151; 1271-1275, 1993.
5. Blana A,Walter B, et al: High-Intensity Focused Ultrasound for the Treatment of Localized Prostate Cancer: 5-Year Experience,Urology 63 (2) 297-300, 2004.
6. Thuroff S, Chaussy C, et al: High-Intensity Focused Ultrasound and Localized Prostate Cancer: Efficacy Results from the European Multicentric Study, Journal of Endourology, Volume 17, Number 8, October 2003.
7.Sanghvi NT, Foster RS, et al:Noninvasive Surgery of Prostate Tissue by High Intensity Focused Ultrasound: An Updated Report, European Journal of Ultrasound, 9 19-29, 1999.
8. Chaussy CG, Thuroff S, High Intensity Focused Ultrasound in Localized Prostate Cancer, J Endourol 14:293-299, 2000.
9.Vallancien G, Prapotnich, et al: Transrectal Focused Ultrasound Combined with Transurethral Resection of the Prostate for the Treatment of Localized Prostate Cancer : Feasibility Study, Journal of Urology, 171 2265-2267, June 2004.
10.Gelet A, Chapelon J: Local Recurrence of Prostate Cancer After External Beam Radiotherapy: Early Experience of Salvage Therapy Using High-Intensity Focused Ultrasonography, Urology 63 (4), 625-629, April 2004.
11.Madersbacher S, Pedevilla M, et al: Effect of High-Intensity Focused Ultrasound on Human Prostate Cancer in Vivo, Cancer Research, 55 3346-3351, August 1, 1995.
12.Uchida T, Tsmura H: Transrectal Focused Ultrasound for Treatment of Patients with Stage T1b-2N0M0 Localized Prostate Cancer: A Preliminary Report, Japanese Journal of Endourology and ESWL,18 (1) 108-114, 2003.
13.Uchida T, Sanghvi N:Transrectal High-Intensity Focused Ultrasound for Treatment of Patients with Stage T1b-2N0M0 Localized Prostate Cancer: A Preliminary Report, Urology, 59 (1) 394-399, 2002.
14. Clement G: Perspectives in Clinical Uses of High-Intensity Focused Ultrasound, Ultrasonics 42 1087-1093, 2004.
15. Long JP, Bahn D, Lee F, Shinohara K, Chinn DO, Macaluso JN, Jr. Five-year retrospective, multi-institutional pooled analysis of cancer related outcomes after cryosurgical ablation of the prostate. Urology 2001 March; 57(3):518-23.
16.Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, Wishnow KI, Kaplan I, Loughlin KR, Richie JP, Kantoff PW. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol 1998 January;16(1):275-83.
17. Shrader-Bogen CL, Kjellberg JL, McPherson CP,Murray CL. Quality of life and treatment outcomes: prostate carcinoma patients’ perspectives after prostatectomy or radiation therapy. Cancer 1997 May 15; 79(10):1977-86.
18. Lim AJ, Brandon AH, Fiedler J, Brickman AL, Boyer CI, Raub WA, Jr., Soloway MS. Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J Urol 1995 October;154(4):1420-5.
19.Walsh PC. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol 2000 June; 163(6):1802-7.
20. Tsujimura A, Matsumiya K, Miyagawa Y, Takaha N, Nishimura K, Nonomura N, Mori N, Hara T, Yamaguchi S, Takahara S, Okuyama A. Relation between erectile dysfunction and urinary incontinence after nerve-sparing and non-nerve-sparing radical prostatectomy. Urol Int 2004;73(1):31-5.
21.Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000 January; 55(1):58-61.
22. Fossa SD, Woehre H, Kurth KH, Hetherington J, Bakke H, Rustad DA, Skanvik R. Influence of urological morbidity on quality of life in patients with prostate cancer. Eur Urol 1997;31 Suppl 3:3-8.
23.Ragde H, Blasko JC, Grimm PD, Kenny GM, Sylvester JE, Hoak DC, Landin K,Cavanagh W.Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 1997 August 1; 80(3):442-53.
24. Theodorescu D, Gillenwater JY, Koutrouvelis PG. Prostatourethral-rectal fistula after prostate brachytherapy. Cancer 2000 November 15; 89(10):2085-91.
25.Merrick GS, Butler WM, Dorsey AT, Galbreath RW, Blatt H, Lief JH. Rectal function following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000 October 1;48(3):667-74.
26.Merrick GS, Butler WM, Dorsey AT, Lief JH, Walbert HL, Blatt HJ. Rectal dosimetric analysis following prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999 March 15; 43(5):1021-7.
27. Stone NN, Stock RG. Complications following permanent prostate brachytherapy. Eur Urol 2002 April; 41(4):427-33.
28. Onik G, Narayan P, Vaughan D, Dineen M, Brunelle R. Focal “nerve-sparing” cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology 2002 July;60(1):109-14.
29. Donnelly BJ, Saliken JC, Ernst DS, li-Ridha N, Brasher PM,Robinson JW, Rewcastle JC. Prospective trial of cryosurgical ablation of the prostate: five-year results. Urology 2002 October; 60(4):645-9.
30. Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002 August; 60(2 Suppl 1): 3-11.
31.Katz AE and Rewcastle JC.The current and potential role of cryoablation as a primary therapy for the treatment of localized prostate cancer. Curr Oncol Rep. 2003 May; 5(3):231-8 Review.
32. Gelet A, Chapelon JY, Bouvier R et al. Transrectal high intensity focused ultrasound and localized prostate cancer: May the nadir PSA predict the treatment success? Eur Urol. 2003;1 (Suppl 2): 134.
33. Zincke H. Radical prostatectomy and exenterative procedures for local failure after radiotherapy with curative intent: comparison of outcomes. J Urol 1992 March;147(3 Pt 2):894-9.